Financing Supports Ongoing Phase 1 Trial of SQZ APC Platform in HPV+ Tumors and Advancement of SQZ AAC Platform towards an Investigational New Drug Application Company Also Announces Expansion of Portfolio into Infectious Diseases and Development of Point-of-Care System WATERTOWN, Mass., May 18, 2020-- SQZ Biotechnologies Company (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the completion of a $65 million Series D preferred stock financing.